Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib

Annals of Oncology

Volumn 19, Issue 2, 2008, Pages 265-268

  Tamaskar, I ^a   Bukowski, R ^a   Elson, P ^a   Ioachimescu, A G ^b   Wood, L ^a   Dreicer, R ^a   Mekhail, T ^a   Garcia, J ^a   Rini, B I ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Metastatic renal cell carcinoma; Sorafenib; Thyroid function abnormalities

Indexed keywords

LEVOTHYROXINE; LIOTHYRONINE; SORAFENIB; SUNITINIB; THYROGLOBULIN ANTIBODY; THYROID HORMONE; THYROTROPIN; THYROXINE;

ADULT; AGED; ARTICLE; DRUG EFFECT; DRUG WITHDRAWAL; EUTHYROID SICK SYNDROME; FEMALE; FREE THYROXINE INDEX; HORMONAL THERAPY; HORMONE SUBSTITUTION; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; KIDNEY CARCINOMA; KIDNEY METASTASIS; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SIDE EFFECT; SYMPTOMATOLOGY; THYROID DISEASE; THYROID FUNCTION; THYROID FUNCTION TEST;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; BENZENESULFONATES; CARCINOMA, RENAL CELL; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOTHYROIDISM; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PYRIDINES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; THYROID FUNCTION TESTS;

EID: 38849093794     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm483     Document Type: Article

References (13)

1. Wilhelm S, Garter S, Tang et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006; 5: 835-844.
2. Carlomagno F, Arraganti S, Guida T et al. BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 2006; 98: 326-334.
3. Ratain MJ, Eisen T, Stadler WM. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 2505-2512. Epub 24 April 2006.
4. Escudier B, Eisen T, Stadler W et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-134.
5. Rini BI, Tamaskar I, Shaheen P et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitnib. J Natl Cancer Inst 2007; 99: 81-83.
6. Desai J, Yassa L, Marqusee E et al. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 2006; 145(9): 660-664.
7. Ramsden JD. Angiogenesis in the thyroid gland. J Endocrinol 2000; 166: 475-480.
8. Viglietto G, Romano A, Manzo G et al. Upregulation of the angiogenic factors PIGF, VEGF and their receptors (Flt-1, Flk-1/KDR) by TSH in cultured thyrocytes and in the thyroid gland of thiouracil-fed rats suggest a TSH-dependent paracrine mechanism for goiter hypervacularisation. Oncogene 1997; 15: 2687-2698.
9. Wang JF, Milosvesci V, Schramek C et al. Presence and possible role of vascular endothelial growth factor in thyroid cell growth and function. J Endocrinol 1998; 157: 5-12.
10. Katoh R. Angiogenesis in endocrine glands: Special reference to the expression of vascular endothelial growth factor. Microsc Res Tech 2003; 60: 181-185.
11. Mendel DB, Laird D, Xin X et al. In vivo antitumour activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endotherlial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003; 9: 327-337.
12. Takahashi M, Buma Y, Iwamoto T et al. Cloning and expression of the ret proto-oncogene encoding a receptor tyrosine kinase with two potential transmembrane domains. Oncogene 1988; 3: 571-578.
13. Nakamura T, Ishizaka Y, Nagao M et al. Expression of the ret proto-oncogene product in human normal and neoplastic tissues of neural crest origin. J Pathol 1994; 172: 255-260.